• Traitements

  • Traitements localisés : découverte et développement

  • Appareil digestif (autre)

Eosinophil depletion suppresses radiation-induced small intestinal fibrosis

Menée in vitro et l'aide d'un modèle murin, cette étude montre que réduire l'accumulation des éosinophiles dans la sous-muqueuse de l'intestin grêle après une irradiation abdominale réduit le risque de fibrose liée aux rayonnements ionisants

Radiation-induced intestinal fibrosis (RIF) is a serious complication after abdominal radiotherapy for pelvic tumor or peritoneal metastasis. Herein, we show that RIF is mediated by eosinophil interactions with

α-smooth muscle actin

–positive (

α-SMA+) stromal cells. Abdominal irradiation caused RIF especially in the submucosa (SM) of the small intestine, which was associated with the excessive accumulation of eosinophils in both human and mouse. Eosinophil-deficient mice showed markedly ameliorated RIF, suggesting the importance of eosinophils. After abdominal irradiation, chronic crypt cell death caused elevation of extracellular adenosine triphosphate, which in turn activated expression of C-C motif chemokine 11 (CCL11) by pericryptal α-SMA+ cells in the SM to attract eosinophils in mice. Inhibition of C-C chemokine receptor 3 (CCR3) by genetic deficiency or neutralizing antibody (Ab) treatment suppressed eosinophil accumulation in the SM after irradiation in mice, suggesting a critical role of the CCL11/CCR3 axis in the eosinophil recruitment. Activated α-SMA+ cells also expressed granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate eosinophils. Transforming growth factor-β1 from GM-CSF

–stimulated eosinophils promoted collagen expression by

α-SMA+ cells. In translational studies, treatment with a newly developed interleukin-5 receptor α

–targeting Ab, analogous to the human agent benralizumab, depleted intestinal eosinophils and suppressed RIF in mice. Collectively, we identified eosinophils as a crucial factor in the pathogenesis of RIF and showed potential therapeutic strategies for RIF by targeting eosinophils.

Science Translational Medicine 2018

Voir le bulletin